Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner

Apoptosis

Volumn 19, Issue 11, 2014, Pages 1616-1626

  Yoon, Sun Ok ^a   Zapata, Mariana C ^a   Singh, Akannsha ^a   Jo, Wol Soon ^b   Spencer, Nakia ^a   Choi, Yong Sung ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

Apoptosis; Gamma secretase inhibitor; Notch; Synergy; T ALL; Vincristine

Indexed keywords

ASPARAGINASE; CASPASE 3; CYTARABINE; GAMMA SECRETASE INHIBITOR; METHOTREXATE; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE; [ (TERT BUTOXYCARBONYLAMINO) 6 PHENYL (4R) HYDROXY (2R) BENZYL HEXANOYL) L LEUCY L PHENYLALANINAMIDE]; [2 [2 (3,5 DIFLUOROPHENYL) ACETYLAMINO] N (1 METHYL 2 OXO 5 PHENYL 2,3 DIHYDRO 1H BENZO[E] [1,4] DIAZEPIN 3 YL) PROPIONAMIDE]; [N [N (3,5 DIFLUOROPHENACETYL) L ALANYL] (S) PHENYLGLYCINE TERT BUTYL ESTER]; ANTINEOPLASTIC AGENT; CASPASE; DIPEPTIDE; N-(N-(3,5-DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT-BUTYL ESTER; NOTCH RECEPTOR; SECRETASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HELA CELL LINE; HUMAN; HUMAN CELL; JURKAT CELL LINE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS; MITOSIS INHIBITION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DIPEPTIDES; DRUG RESISTANCE; DRUG SYNERGISM; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, NOTCH; VINCRISTINE;

EID: 84910155132     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-1029-5     Document Type: Article

References (33)

1. Pui CH, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178
2. Kraszewska MD, Dawidowska M, Szczepanski T, Witt M (2012) T-cell acute lymphoblastic leukaemia: recent molecular biology findings. Br J Haematol 156:303-315
3. Van Vlierberghe P, Ferrando A (2012) The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 122:3398-3406
4. Grabher C, von Boehmer H, Look AT (2006) Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 6:347-359
5. Koch U, Radtke F (2011) Notch in T-ALL: new players in a complex disease. Trends Immunol 32:434-442
6. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB et al (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306:269-271
7. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B et al (1996) Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 183:2283-2291
8. Chen J, Jette C, Kanki JP, Aster JC, Look AT et al (2007) NOTCH1-induced T-cell leukemia in transgenic zebrafish. Leukemia 21:462-471
9. Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD et al (2003) Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 23:655-664
10. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ (2007) Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 110:278-286
11. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D et al (2007) FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204:1813-1824
12. De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L et al (2008) In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 93:533-542
13. Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E et al (2012) Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 11:1565-1575
14. Masuda S, Kumano K, Suzuki T, Tomita T, Iwatsubo T et al (2009) Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Sci 100:2444-2450
15. Tammam J, Ware C, Efferson C, O'Neil J, Rao S et al (2009) Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol 158:1183-1195
16. Wei P, Walls M, Qiu M, Ding R, Denlinger RH et al (2010) Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 9:1618-1628
17. Rao S, O'Neil J, Liberator C, Hardwick J, Dai X et al (2009) Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 69:3060-3068
18. Cullion K, Draheim K, Hermance N, Tammam J, Sharma V et al (2009) Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 113:6172-6181
19. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG et al (2014) An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet 46:364-370
20. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E et al (2009) Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15:50-58
21. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K et al (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13:1203-1210
22. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G et al (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-390
23. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT et al (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398:513-517
24. Placanica L, Chien JW, Li YM (2010) Characterization of an atypical gamma-secretase complex from hematopoietic origin. Biochemistry 49:2796-2804
25. Maillard I, Weng AP, Carpenter AC, Rodriguez CG, Sai H et al (2004) Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 104:1696-1702
26. Lewis HD, Leveridge M, Strack PR, Haldon CD, O'Neil J et al (2007) Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 14:209-219
27. Holleman A, den Boer ML, Kazemier KM, Janka-Schaub GE, Pieters R (2003) Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood 102:4541-4546
28. Akiyoshi T, Nakamura M, Yanai K, Nagai S, Wada J et al (2008) Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology 134:131-144
29. Tasaka T, Akiyoshi T, Yamaguchi K, Tanaka M, Onishi H et al (2010) Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes. Anticancer Res 30:4999-5010
30. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA et al (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000
31. Boeras DI, Granic A, Padmanabhan J, Crespo NC, Rojiani AM et al (2008) Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiol Aging 29:319-328
32. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C et al (2002) The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99:4100-4108
33. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M et al (2004) Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103:3905-3914